Discovery and Advancement of Chikungunya virus inhibitors
Discovery and Advancement of Chikungunya virus inhibitors
批准号:
8905316
负责人:
Daniel C Pevear
金额:
$30.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2017-02-28
关键词:
AddressAlphavirusAmericasAnimal ModelAntiviral AgentsArthralgiaAttenuatedBioavailableBiological AssayBiological AvailabilityCaribbean regionCategoriesCell Culture TechniquesCellsCentral AmericaChemicalsChikungunya virusClinicalCollaborationsCollectionCulicidaeCytopathologyDevelopmentEpidemicExhibitsFeasibility StudiesGoalsGrantHandHumanLaboratoriesLeadLibrariesLiquid substanceMedicalModelingMolecular WeightMorbidity - disease rateNational Institute of Allergy and Infectious DiseaseOralOutcomePharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhasePreventionPropertyRageRodentSeriesSmall Business Innovation Research GrantSpecificityStructure-Activity RelationshipSystemTestingTexasTimeTogaviridaeUnited StatesUniversitiesVaccinesVero CellsViralVirusVirus DiseasesVirus InhibitorsVirus ReplicationWorkanalogbasecandidate selectioncytotoxicityexperiencefollow-uphigh throughput screeninginhibitor/antagonistinterestlead seriesnonhuman primatenovelpathogenpublic health relevancescreeningsmall moleculesmall molecule librariessuccesstransmission process
中文摘要
描述(由申请人提供):迫切需要基孔肯雅病毒(CHIKV)的新型抑制剂来解决这种病原体在美洲的惊人传播。该I期SBIR可行性研究的目的是鉴定特异性和选择性抑制细胞培养物中CHIKV复制的多达3种药物样化合物先导系列。为此我们
已经开发并验证了一种高通量筛选测定法,其适用于针对细胞培养物中的活性CHIKV复制的化合物筛选。我们将对超过100,000种具有最佳药物样特性的化合物库进行高通量抗CHIKV筛选活动。将对该活动中出现的质量命中进行效力、选择性、针对CHIKV和相关甲病毒的活性谱以及作用机制的分析。最有趣的化合物系列将经历药物化学打击领导的努力,探索结构-活性关系(SAR)。将对每个系列中代表性化合物的口服生物利用度进行早期评估。成功将触发第二阶段SBIR赠款的提交,这将推动该系列的化学优化,以“候选人选择预开发”。第二阶段将包括在UTMB的Weaver博士的实验室中在CHIKV疾病的动物模型中进行概念验证测试。本文所述的工作预计将导致鉴定一种或多种急需的靶向基孔肯雅病毒的抑制剂系列。
英文摘要
DESCRIPTION (provided by applicant): Novel inhibitors of Chikungunya virus (CHIKV) are urgently needed to address the alarming spread of this pathogen across the Americas. The objective of this Phase I SBIR feasibility study is to identify up to 3 drug-like compound lead series that specifically and selectively inhibit CHIKV replication in cell culture. To this end, we
have developed and validated a high-throughput screening assay that is suitable for compound screening against active CHIKV replication in cell culture. We will conduct a high-throughput anti-CHIKV screening campaign of a library of over 100,000 compounds with optimal drug-like properties. Quality hits that emerge from this campaign will be profiled for potency, selectivity, spectrum of activity against CHIKV and related alphaviruses, and mechanism of action. The most interesting of the compound series will undergo medicinal chemistry hit-to-lead efforts to explore structure-activity relationships (SAR). Early assessment of the oral bioavailable of representative compounds from each series will be undertaken. Success will trigger the submission of a Phase II SBIR grant that will drive chemical optimization of the series to "Candidate Selection for Pre-development". Phase II will include Proof of Concept testing in animal models of CHIKV disease in the laboratory of Dr. Weaver at UTMB. The work described herein is expected to lead to the identification of one or more urgently needed inhibitor series that target Chikungunya virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
-
批准号:9048725
-
项目类别:
-
资助金额:$113.91万
-
财政年份:2016
-
负责人:Daniel C Pevear
-
依托单位:
Advancement of antiviral inhibitors of chikungunya virus
-
批准号:10132230
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2015
-
负责人:Daniel C Pevear
-
依托单位:
CCR5 inhibitors that block HIV but not chemokines
-
批准号:6887677
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2004
-
负责人:Daniel C Pevear
-
依托单位:
Development of Small-Molecule HIV Entry Inhibitors
-
批准号:6792155
-
项目类别:
-
资助金额:$87.43万
-
财政年份:2001
-
负责人:Daniel C Pevear
-
依托单位:
海外基金